
|Videos|October 7, 2017
CD101: A New Long-Acting Echinocandin
Author(s)Contagion® Editorial Staff
David Andes, MD, shares the half-life and dosing intervals for a new long-acting echinocandin.
Advertisement
David Andes, MD, professor and chief of infectious disease at the University of Wisconsin, shares the half-life and dosing intervals for a new long-acting echinocandin.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
From Awareness to Prevention: Addressing the Infection–Mental Illness–Violence Continuum
2
Once-Weekly Oral Islatravir Plus Lenacapavir Maintains HIV Suppression Through 48 Weeks
3
WHO Finds Progress in Malaria Prevention Measures
4
WHO Certifies Countries as Malaria Free in Face of Persistent Antimalarial Drug Resistance
5






























































































































































































































































































































